JP7817179B2 - 神経刺激性ステロイド及びその使用方法 - Google Patents

神経刺激性ステロイド及びその使用方法

Info

Publication number
JP7817179B2
JP7817179B2 JP2022556035A JP2022556035A JP7817179B2 JP 7817179 B2 JP7817179 B2 JP 7817179B2 JP 2022556035 A JP2022556035 A JP 2022556035A JP 2022556035 A JP2022556035 A JP 2022556035A JP 7817179 B2 JP7817179 B2 JP 7817179B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
group
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022556035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518411A (ja
JPWO2021188778A5 (https=
JP2023518411A5 (https=
Inventor
フランセスコ ジー． サリトゥロ，
マーシャル リー モーニングスター，
マリア ヘスス ブランコ－ピヤド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2023518411A publication Critical patent/JP2023518411A/ja
Publication of JPWO2021188778A5 publication Critical patent/JPWO2021188778A5/ja
Publication of JP2023518411A5 publication Critical patent/JP2023518411A5/ja
Priority to JP2025188453A priority Critical patent/JP2026021531A/ja
Application granted granted Critical
Publication of JP7817179B2 publication Critical patent/JP7817179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0095—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 carbon in position 21 is part of carboxylic group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022556035A 2020-03-18 2021-03-18 神経刺激性ステロイド及びその使用方法 Active JP7817179B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025188453A JP2026021531A (ja) 2020-03-18 2025-11-07 神経刺激性ステロイド及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991234P 2020-03-18 2020-03-18
US62/991,234 2020-03-18
PCT/US2021/022933 WO2021188778A2 (en) 2020-03-18 2021-03-18 Neuroactive steroids and their methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025188453A Division JP2026021531A (ja) 2020-03-18 2025-11-07 神経刺激性ステロイド及びその使用方法

Publications (4)

Publication Number Publication Date
JP2023518411A JP2023518411A (ja) 2023-05-01
JPWO2021188778A5 JPWO2021188778A5 (https=) 2024-03-29
JP2023518411A5 JP2023518411A5 (https=) 2024-03-29
JP7817179B2 true JP7817179B2 (ja) 2026-02-18

Family

ID=75478218

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022556035A Active JP7817179B2 (ja) 2020-03-18 2021-03-18 神経刺激性ステロイド及びその使用方法
JP2025188453A Pending JP2026021531A (ja) 2020-03-18 2025-11-07 神経刺激性ステロイド及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025188453A Pending JP2026021531A (ja) 2020-03-18 2025-11-07 神経刺激性ステロイド及びその使用方法

Country Status (10)

Country Link
US (1) US20240239835A9 (https=)
EP (1) EP4121438A2 (https=)
JP (2) JP7817179B2 (https=)
CN (1) CN115551874A (https=)
AR (1) AR121609A1 (https=)
AU (1) AU2021238346A1 (https=)
CA (1) CA3175324A1 (https=)
IL (1) IL296371A (https=)
TW (1) TW202143976A (https=)
WO (1) WO2021188778A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
CN113166193B (zh) 2018-10-12 2025-08-19 萨奇治疗股份有限公司 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇
KR20250124139A (ko) * 2022-11-21 2025-08-19 세이지 테라퓨틱스, 인크. 음성 nmda-조정 화합물 및 이의 사용 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020118060A1 (en) 2018-12-05 2020-06-11 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2020243488A1 (en) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
WO2021142477A1 (en) 2020-01-12 2021-07-15 Brii Biosciences, Inc. Neuroactive steroids and pharmaceutical composition containing the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
FI972202L (fi) * 1994-11-23 1997-07-17 Cocensys Inc Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun
RU2194712C2 (ru) * 1995-06-06 2002-12-20 Коукенсис, Инк. НЕЙРОАКТИВНЫЕ СТЕРОИДЫ, ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ НАРУШЕНИЙ, СПОСОБ ИНДУКЦИИ СНА И СПОСОБ ИНДУКЦИИ АНЕСТЕЗИИ С ИХ ИСПОЛЬЗОВАНИЕМ, СПОСОБ МОДУЛИРОВАНИЯ КОМПЛЕКСА РЕЦЕПТОР ГАМКa-ХЛОРИДНЫЙ ИОНОФОР
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
HRP20230747T1 (hr) * 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
ME03809B (me) * 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
WO2020135454A1 (zh) * 2018-12-26 2020-07-02 张家口华健致远生物科技有限公司 一类类固醇化合物及其用途
CN112391512B (zh) * 2019-08-13 2022-03-18 宝山钢铁股份有限公司 一种高磁感取向硅钢及其制造方法
JP2024074633A (ja) * 2022-11-21 2024-05-31 小松ウオール工業株式会社 間仕切り装置と、間仕切り装置における横桟の支持構造

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020118060A1 (en) 2018-12-05 2020-06-11 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2020243488A1 (en) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
WO2021142477A1 (en) 2020-01-12 2021-07-15 Brii Biosciences, Inc. Neuroactive steroids and pharmaceutical composition containing the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Angew. Chem. Int. Ed. ，2018年，57，744-748
Cell Chemical Biology ，2017年，24，458-470
Nature Commun. ，2018年，9，2841(1-8)
Org. Lett. ，2019年，21，7804-7808
Tetrahedron ，1983年，39，2709-2713

Also Published As

Publication number Publication date
CA3175324A1 (en) 2021-09-23
JP2023518411A (ja) 2023-05-01
WO2021188778A2 (en) 2021-09-23
US20240239835A9 (en) 2024-07-18
EP4121438A2 (en) 2023-01-25
IL296371A (en) 2022-11-01
CN115551874A (zh) 2022-12-30
WO2021188778A3 (en) 2021-10-28
US20230183288A1 (en) 2023-06-15
TW202143976A (zh) 2021-12-01
AR121609A1 (es) 2022-06-22
JP2026021531A (ja) 2026-02-10
AU2021238346A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
JP7817179B2 (ja) 神経刺激性ステロイド及びその使用方法
JP7720948B2 (ja) 神経刺激性ステロイド及びその使用方法
JP7817214B2 (ja) ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物
JP7670626B2 (ja) 神経刺激性ステロイド及びその組成物
JP7754725B2 (ja) Ｃｎｓ障害を治療するための組成物及び方法
JP2024114787A (ja) Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法
JP7692830B2 (ja) ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物
JP7671244B2 (ja) Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド
EA049422B1 (ru) Нейроактивные стероиды и их композиции

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260205

R150 Certificate of patent or registration of utility model

Ref document number: 7817179

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150